ATE126061T1 - Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum. - Google Patents

Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.

Info

Publication number
ATE126061T1
ATE126061T1 AT91309994T AT91309994T ATE126061T1 AT E126061 T1 ATE126061 T1 AT E126061T1 AT 91309994 T AT91309994 T AT 91309994T AT 91309994 T AT91309994 T AT 91309994T AT E126061 T1 ATE126061 T1 AT E126061T1
Authority
AT
Austria
Prior art keywords
prophylaxis
treatment
lithium
molluscum
lithium compound
Prior art date
Application number
AT91309994T
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE126061T1 publication Critical patent/ATE126061T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Materials For Medical Uses (AREA)
AT91309994T 1990-10-31 1991-10-30 Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum. ATE126061T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909023701A GB9023701D0 (en) 1990-10-31 1990-10-31 Medical treatment

Publications (1)

Publication Number Publication Date
ATE126061T1 true ATE126061T1 (de) 1995-08-15

Family

ID=10684665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91309994T ATE126061T1 (de) 1990-10-31 1991-10-30 Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.

Country Status (11)

Country Link
US (1) US5223271A (de)
EP (1) EP0484112B1 (de)
JP (1) JPH06263644A (de)
AT (1) ATE126061T1 (de)
AU (1) AU645359B2 (de)
CA (1) CA2052246A1 (de)
DE (1) DE69111974T2 (de)
DK (1) DK0484112T3 (de)
GB (1) GB9023701D0 (de)
GR (1) GR3017855T3 (de)
IE (1) IE71171B1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756107A (en) * 1994-12-21 1998-05-26 Cosmederm Technologies Formulations and methods for reducing skin irritation
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
WO1999018797A1 (en) * 1997-10-09 1999-04-22 Emory University Method and devices for transdermal delivery of lithium
FR2783424B1 (fr) * 1998-09-03 2002-10-04 Labcatal Utilisation du gluconate de lithium dans la fabrication d'un medicament pour le traitement de l'herpes et de la dermite seborrheique
DE60023180D1 (de) * 1999-12-30 2006-02-23 Henderson Morley Res & Dev Ltd Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ES2164018B1 (es) * 2000-05-26 2003-06-16 Inst De Salud Carlos Iii Empleo de una sal de litio en la elaboracion de un medicamento para el tratamiento de la infeccion causada por el virus respiratorio sincitial humano (vrdh)
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
EP2143421A1 (de) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Zusammensetzung zur topischen Behandlung von Strahlenkeratose
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
WO2012125941A1 (en) * 2011-03-17 2012-09-20 Follica, Inc. Lithium treatment for microbial infections
CN113648278A (zh) * 2013-05-03 2021-11-16 立普妥公司 用于给药的运载体和局部组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639625A (en) * 1967-07-13 1972-02-01 Lewis Sherwin Compositions containing lithium succinate
US4396452A (en) 1978-12-21 1983-08-02 Monsanto Company Process for point-bonding organic fibers
JPS5590505A (en) 1978-12-29 1980-07-09 Kureha Chem Ind Co Ltd Carboxyalkylchitin and preparation of deacetylated product thereof
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
AU556817B2 (en) * 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8318912D0 (en) * 1983-07-13 1983-08-17 Horrobin D F Compositions for treatment of skin/hair
GB8320203D0 (en) * 1983-07-27 1983-09-01 Horrobin D F Anti-viral compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
ES2040847T3 (es) * 1987-04-27 1996-07-16 Efamol Holdings Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio.

Also Published As

Publication number Publication date
AU8687391A (en) 1992-05-07
AU645359B2 (en) 1994-01-13
DE69111974D1 (de) 1995-09-14
DK0484112T3 (da) 1995-09-18
JPH06263644A (ja) 1994-09-20
EP0484112A2 (de) 1992-05-06
EP0484112B1 (de) 1995-08-09
CA2052246A1 (en) 1992-05-01
GR3017855T3 (en) 1996-01-31
GB9023701D0 (en) 1990-12-12
IE71171B1 (en) 1997-01-29
IE913787A1 (en) 1992-05-22
EP0484112A3 (en) 1992-07-08
US5223271A (en) 1993-06-29
DE69111974T2 (de) 1996-01-04

Similar Documents

Publication Publication Date Title
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
LV10180A (lv) Farmaceitiska kompozicija
DE3382458D1 (de) Haarwuchsmittel.
MX9203543A (es) Medicamento.
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ATE100320T1 (de) Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DK347289A (da) Terapeutiske forbindelser
MY104521A (en) Treatment of depression.
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DK277387A (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
ATE78160T1 (de) Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee